Eisai Co. Ltd., which will manufacture and market the drug; Arena will draw a royalty on global sales. The sale completes a pivot in emphasis toward drugs still under development. Drugs in the company's pipeline includes medications designed to treat pain, ulcerative colitis and pulmonary arterial hypertension. , potential products that had not yet been approved by the FDA included Temanogrel (thrombotic diseases), Ralinepag (pulmonary arterial hypertension), APD334 (autoimmune disease), APD371 (pain), and Nelotanserin. In 2018, Arena's etrasimod, a drug directed at treating ulcerative colitis (and a competitor with ozanimod from Celgene), passed phase II clinical trials successfully and moved on to phase III. See also List of biotechnology companies References External links Official website Biotechnology companies of the United States Pharmaceutical companies of the United States Biopharmaceutical companies Companies based in San Diego American companies established in 1997 Biotechnology companies established in 1997 Pharmaceutical companies established in 1997 1997 establishments in California Health care companies based in California Companies formerly listed on the Nasdaq 2022 mergers and acquisitions Pfizer